<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962376</url>
  </required_header>
  <id_info>
    <org_study_id>YZHANG0001</org_study_id>
    <nct_id>NCT01962376</nct_id>
  </id_info>
  <brief_title>Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis</brief_title>
  <official_title>Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators assessed whether the addition of a preoperative regimen of Bevacizumab
      regimen to improves R0 resection rate and survival among patients with potentially resectable
      gastric cancer with liver metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Groups 1:Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially
      Resectable Gastric Cancer With Liver Metastasis.

      Groups 2:Capecitabine Plus Oxaliplatin With placebo in Patients With Potentially Resectable
      Gastric Cancer With Liver Metastasis.

      Group 1 compare with Group 2 in disease-free survival time. Stage I：Preoperative therapy
      Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin
      alines.

      Stage II: therapy after surgery Capecitabine Plus Oxaliplatin With Bevacizumab is superior to
      Capecitabine Plus Oxaliplatin alones after surgery for over 6 months in all.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Side effects during observation] Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Bevacizumab,postoperative chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
placebo:Physiological saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin;Capecitabine</intervention_name>
    <description>A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.</description>
    <arm_group_label>Bevacizumab,postoperative chemotherapy</arm_group_label>
    <arm_group_label>Preoperative Chemotherapy</arm_group_label>
    <other_name>Oxaliplatin plus capecitabine other names:XELOX.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin;Capecitabine;Bevacizumab</intervention_name>
    <description>A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.</description>
    <arm_group_label>Bevacizumab,postoperative chemotherapy</arm_group_label>
    <arm_group_label>Preoperative Chemotherapy</arm_group_label>
    <other_name>Capecitabine Plus Oxaliplatin Other names XELOX.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Pathological tissue were gastric cancer by gastric and liver biopsy.

             2.Immunohistochemistry confirmed HER-2 ( - ).

             3.The number of liver metastasis is less than 3 and evey one is less than 5 cm.

             4.Liver metastasis must be clinically limited to Type H1 or Type H2.

             5.gastric cancer were able to resectable lesions or T1-4a N1-2 M0.

             6.Patients•had not received radiotherapy past and not other organ metastasis and
             peritoneal metastasis.

             7.Karnofsky performance status performance status &gt;70.

             8.Inadequate hematopoietic function： Hemoglobin≥90g/L;
             ANC≥1,500/mm3;Platelet≥100,000/mm3

             9.Inadequate organ function which is defined as below: Total bilirubin≤1.5 pper limit
             of normal range (ULN);alanine transaminase / Aspertate aminotransferase≤2.5 upper
             limit of normal range (ULN) (≤5.0 x ULN if hepatic metastasis); serum creatinine≤1.5
             pper limit of normal range (ULN), Serum albumin≥30g/L.

             10.expectancy must be more than 3 months.

             11.the random blood or urine pregnancy test in fertile woman must be the negative
             results in pregnancy test in 7 days.

             12.Patients for male and female used reliable contraception contraceptive method until
             the end of study 30 days later.

        Type H1: only one leaf with liver metastasis. Type H2: two leaves with a few scattered
        metastatic in liver.

        Exclusion Criteria:

          -  1. Patients with other extrahepatic metastasis Include peritoneal metastasis.

             2. Primary was ulcerative type or the existence of the perforation.

             3. Patients with other malignancy in 5 years.

             4. Patients with severe liver disease, kidney disease, respiratory disease ,
             uncontrolled diabetes or severe infections.

             5.Patients with hypertension failed to control, active bleeding, 3~4 proteinuria, heal
             the wound, thromboembolisms, heart failure, clinical symptoms of heart disease.

             6.Patients have obvious peripheral nervous system disorders,mental disorders and
             disorders of the central nervous system history.

             7.Patients have history of organ transplantation.

             8.Patients with any medical or psychiatric condition or disease which, in the
             investigator's judgment, would make the patient inappropriate for entry into this
             study.

             9.Patients combined antitumor drug outside the research program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine-Oncology</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhang, Doctor</last_name>
      <phone>+8613315978336</phone>
      <email>13315978336@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Yan Zhang</investigator_full_name>
    <investigator_title>The first hospital of Shijiazhuang city</investigator_title>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Potentially Resectable Gastric Cancer Liver Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

